T1	Participants 70 88	pancreatic cancer:
T2	Participants 399 503	resectable pancreatic cancer patients treated with adjuvant gemcitabine compared with untreated patients
T3	Participants 645 675	Tissue samples of 162 patients
T4	Participants 1432 1458	pancreatic cancer patients
